Updated on 22 May 2015
The global market for Pancreatic Cancer is $1 billion, and for HCC Liver Cancer an additional $1.4 billion
Singapore: Australia-based lifesciences company Oncosil Medical recently announced the commercialization of its device-OncoSil in the European Union. OncoSil is device that provides localized radiation treatment for cancer, and is the company's lead product candidate.
Oncosil, implantable nuclear medicine (radiotherapy) device, has been successfully piloted for treating pancreatic and liver cancer. The device was found to be safe and effective in laboratory studies and has clinically demonstrated target tumor regression (tumour shrinkage) in both solid tumor indications of pancreatic and liver cancer.
Mr Daniel Kenny, CEO, OncoSil, commented, "I am delighted to announce that OncoSil has received ISO Certification in April. This certification is a key requirement for CE mark Approval. We are very excited to be in the forefront of potentially a new radiation treatment for the dreaded disease of pancreatic and liver cancer."
The company also announced the appointment of Professor Pierce Chow as chairman to lead primary liver cancer - hepatocellular carcinoma (HCC) - Scientific Advisory Board.